All In Biotech

Drug Trial Radar · NCT07247162

Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's Syndrome

A Double-blind, Randomised, 30-week Placebo-controlled Phase IV Study to Assess the Efficacy and Safety of Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's Syndrome

Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

63

Planned (sponsor's estimate)

Start

Aug 26, 2026

Primary completion

May 2028

Study completion Jul 2028

Sponsor

Lead sponsor
RECORDATI GROUPIndustry
Sponsor type
Industry
First posted
Nov 25, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Osilodrostat has proven to be a safe and efficacious treatment for patients with CS. Demonstrating normalisation of hypercortisolaemia and in patients with hypertension and/or dysglycaemia clinically relevant and statistically significant reductions in blood pressure and glycaemia. This study aims at providing additional evidence on the safety, efficacy and appropriate dosing of osilodrostat in patients with CS, who have hypertension.

Conditions

  • Hypertension
  • Hypercortisolemia
  • Cushing Syndrome

Interventions

  • OsilodrostatDrug

    Osilodrostat tablets 1 mg and 5 mg for oral useOsilodrostat tablets 1 mg and 5 mg for oral use.During the 18-week titration phase, the dose of the medication will be titrated every 3 weeks based on the cortisolaemic and clinical response to treatment. An independent endocrinologist titration committee will be applied to provide recommendations on dose-titration based on biochemical and clinical response. At the end of the 18-week dose titration phase, participants will enter a 12-week dose maintenance phase, which is also blinded. They will continue with the dose they were receiving at the end of the dose titration phase, unless there is a need to down-titrate or to stop the study medication for safety purposes.

  • PlaceboDrug

    matching placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the efficacy of osilodrostat on the proportion of participants with normalization of urinary-free cortisol (UFC)Time frame: 30 weeks

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • NOLA Care, LLC

    Jacksonville, Florida · Recruiting

  • Diabetes And Endocrinology Associates Of Stark County, Inc.

    Canton, Ohio · Recruiting

  • Texas Valley Clinical Research

    Weslaco, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.